老虎證券

BRIEF-FDA Approves Merck’S WELIREG® (Belzutifan) For The Treatment Of Adults And Pediatric Patients 12 Years And Older With Locally Advanced, Unresectable, Or Metastatic Pheochromocytoma Or Paraganglioma (PPGL)

Reuters
2025/05/15
BRIEF-FDA Approves Merck’S WELIREG® (Belzutifan) For The Treatment Of Adults And Pediatric Patients 12 Years And Older With Locally Advanced, Unresectable, Or Metastatic Pheochromocytoma Or Paraganglioma (PPGL)

May 14 (Reuters) - Merck & Co Inc MRK.N:

  • FDA APPROVES MERCK’S WELIREG® (BELZUTIFAN) FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA (PPGL)

  • MERCK & CO INC: WELIREG LABEL CONTAINS A BOXED WARNING THAT EXPOSURE TO WELIREG DURING PREGNANCY CAN CAUSE EMBRYO-FETAL HARM

Source text: ID:nBw28TVK8a

Further company coverage: MRK.N

((Reuters.Briefs@thomsonreuters.com;))

應版權方要求，你需要登入查看該內容

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10